The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

The drug, suzetrigine, will be sold under the brand name Journavx and is the first new class of pain medicine approved in ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...

The drug, Journavx by Vertex Pharmaceuticals, blocks pain signals to the brain, making it nonaddictive. The Food and Drug ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...

The new non-opioid drug has been approved for the treatment of severe pain, such as that following surgery or an injury.

Each year, about 125 million opioid prescriptions are written for Americans with pain caused by broken bones, burns, ...

U.S. officials have approved a new type of pain drug designed to eliminate the risks of addiction and overdose associated ...

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...

The prescription pills, sold under the brand name Journavx and made by Vertex Pharmaceuticals, are taken twice a day and ...

The FDA’s nod for suzetrigine bolsters confidence in the pharmaceutical industry’s strategy to target sodium channels.